

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Northpond Ventures III GP, LLC</u>			2. Issuer Name and Ticker or Trading Symbol <u>Kyverna Therapeutics, Inc. [KYTX]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) X Other (specify below) _____ Former 10% Owner		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>02/12/2024</u>			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person _____ X Form filed by More than One Reporting Person _____		
<u>7500 OLD GEORGETOWN ROAD, SUITE 800</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	<u>BETHESDA MD 20814</u>		Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/12/2024		C ⁽¹⁾		2,805,426	A	(1)	2,805,426	I	By: Northpond Ventures III, LP ⁽²⁾
Common Stock	02/12/2024		P		450,000	A	\$22	450,000	I	By: Northpond Ventures, LP ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Stock	(1)	02/12/2024		C ⁽¹⁾		12,767,776	(1)	(1)		Common Stock	2,805,426	(1)	0	I	By: Northpond Ventures III, LP ⁽²⁾

1. Name and Address of Reporting Person* <u>Northpond Ventures III GP, LLC</u>		
(Last)	(First)	(Middle)
<u>7500 OLD GEORGETOWN ROAD, SUITE 800</u>		
(Street)	<u>BETHESDA MD 20814</u>	
(City)	(State)	(Zip)
1. Name and Address of Reporting Person* <u>Northpond Ventures III, LP</u>		
(Last)	(First)	(Middle)
<u>7500 OLD GEORGETOWN ROAD, SUITE 800</u>		
(Street)	<u>BETHESDA MD 20814</u>	
(City)	(State)	(Zip)
1. Name and Address of Reporting Person* <u>Rubin Michael P.</u>		
(Last)	(First)	(Middle)
<u>7500 OLD GEORGETOWN ROAD, SUITE 800</u>		

(Street)	BETHESDA	MD	20814
(City)		(State)	(Zip)

Explanation of Responses:

1. Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the "Issuer"), each share of Series B Convertible Preferred Stock, par value \$0.00001 per share (the "Series B Preferred Stock"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value \$0.00001 per share (the "Common Stock"). The Series B Preferred Stock had no expiration date.
2. Northpond Ventures III GP, LLC ("Northpond III LLC") is the general partner of Northpond Ventures III, LP ("Northpond Fund III"), and Michael P. Rubin is the managing member of Northpond III LLC. As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
3. Northpond Ventures GP, LLC ("Northpond LLC") is the general partner of Northpond Ventures, LP ("Northpond Fund"), and Michael P. Rubin is the managing member of Northpond LLC. As a result, Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Mr. Rubin disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any.

Northpond Ventures III GP,
LLC, By: /s/ Patrick Smerkers, 02/12/2024
Chief Financial Officer
Northpond Ventures III, LP, By:
Northpond Ventures III GP,
LLC, its general partner, By: /s/ 02/12/2024
Patrick Smerkers, Chief
Financial Officer
/s/ Michael P. Rubin 02/12/2024
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.